For every HBV DNA measurement of >2,000 IU/mL, as second HBV DNA will be measured after 2 weeks. The primary outcome of the study will be virologic relapse, defined as serum HBV DNA >2,000 IU/mL in both 2 measurements of 2 weeks apart, regardless of serum ALT levels, in which the original NA (entecavir or tenofovir) will be recommenced. We chose HBV DNA >2,000 IU/mL as the threshold for restarting NA as this is the level in which CHB patients would need to be considered for treatment.